Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 19Neoplasm Metastasis 6Neoplasms 4Carcinoma, Squamous Cell 4Squamous Cell Carcinoma of Head and Neck 3Lung Neoplasms 3Brain Neoplasms 3Recurrence 2Head and Neck Neoplasms 2Glioblastoma 2Carcinoma 2Triple Negative Breast Neoplasms 1Thrombocytosis 1Skin Squamous Cell Cancer 1Rare Tumor 1Prostatic Neoplasms 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Penile Neoplasms 1Pancreatic Neoplasms 1Non-small Cell Lung Cancer Metastatic 1NSCLC 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Multiple Myeloma 1Mouth Neoplasms 1Lymphoma, Non-Hodgkin 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Chronic-Phase 1

Interventions

pembrolizumab 4Pemetrexed 4Carboplatin 4Gemcitabine 3Bevacizumab 3tusamitamab ravtansine 2Vinorelbine 2Ramucirumab 2Erlotinib Hydrochloride 2Docetaxel 21-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 2vistusertib 1vandetanib 1telomerase reverse transcriptase p572Y, human 1spartalizumab 1sotorasib 1sintilimab 1olaparib 1necitumumab 1icotinib 1durvalumab 1dacomitinib 1capivasertib 1aumolertinib 1Radiosurgery 1Platinum 1Paclitaxel 1MLN 8237 1LY3023414 1Injections 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Non-small Cell Lung Cancer Metastatic × dacomitinib × Clear all
NCT04504071 2025-09-08

Dacomitinib in Lung Cancer With Uncommon EGFR Mutations

Shanghai Chest Hospital

Phase 2 Active not recruiting
30 enrolled
Thoracic

Non-small Cell Lung Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡